Drug costs are an issue in virtually every country and particularly in the United States.1,2 In this Viewpoint, we describe the process used by the National Institute for Health and Care Excellence (NICE) to appraise cancer drugs.
NICE was established in 1999 to help the National Health Service (NHS) in England and Wales to improve outcomes for patients by providing evidence-based clinical practice guidance. Technology appraisal guidance evaluates the clinical and cost-effectiveness of new drugs, medical devices, and diagnostics and makes recommendations on their use. Between March 2000 and October 2017, 783 recommendations have been published. Cancer technologies constitute 41% of all published technology appraisals.
Dillon A, Landells LJ. NICE, the NHS, and Cancer Drugs. JAMA. 2018;319(8):767–768. doi:10.1001/jama.2017.20552
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: